SynBioLab

SynBioLab was founded in 2017, focusing on the biosynthesis of high value-added plant-derived pharmaceutical compounds. Addressing the pain points of long production cycles, high extraction costs, and some plant-based medicines originating from rare or protected plants, SynBioLab redesigns microbial metabolic pathways and constructs biological cell factories through synthetic biology methods. This allows for a significant reduction in the production cycle and cost of plant-derived compounds without relying on agricultural or forestry land. In the next 2-3 years, SynBioLab will continue to collaborate with industry peers and cross-disciplinary fields, achieving scenario applications of synthetic biology in healthcare, food, consumer goods, and other areas through solid technological innovation. This will realize true green "intelligent" manufacturing, providing more imaginative space for humanity to explore a better life.